<![CDATA[Berzosertib Combo Shows No Response Benefit in Metastatic CRPC]]>

Phase 2negativeberzosertibcarboplatindocetaxelNegative

AI Analysis

Summary

Phase 2 trial of berzosertib combined with carboplatin failed to demonstrate efficacy in heavily pretreated metastatic castration-resistant prostate cancer, with 0% overall response rate compared to 15% for the docetaxel/carboplatin control arm.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Berzosertib/carboplatin produced 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC

Importance:6/10

Sentiment:

-0.90

Phase 2oncologyprostate cancerCRPCnegative resultscombination therapy

Read the original article

Published by Cancer Network on October 5, 2026 3:00 PM

Read Original